Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03983824
Title Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.